Sea4Us, a marine resources biotechnology company based in Sagres and a spin-off of Nova Medical School, has just received the news that it has been approved for funding of 5.96 million euros, awarded by the European Innovation Council (EIC), to advance clinical trials that will allow us to bring an innovative analgesic to the market.
It is a non-opioid, marine-inspired, highly effective treatment for chronic pain, a problem that affects 1.6 billion people worldwide. The therapy developed by Sea4Us eliminates the side effects of current opioid-based drugs without compromising their efficacy.
The European Innovation Council (EIC) is Europe's leading innovation programme for identifying, developing and scaling up innovative technologies.
Created under the Horizon Europe programme, the EIC has a budget of €10.1 billion to support innovations throughout their life cycle.